Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated May 1, 2014 (12 years ago)

Dextroamphetamine Sulfate Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Impurities/Degradation Specifications: this product is being recalled due to an out of specification test result for impurities during stability testing.

Cause type: Impurity / degradation

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present. All impurity / degradation recalls.

What was recalled

Dextroamphetamine Sulfate Tablets, USP, 10 mg, 100-count bottles, Rx only, Barr Laboratories, Inc., Pomona, NY 10970, NDC 0555-0953-02.

Affected NDC 0555-0953-02

Compare with the code on your package — it is the most precise check available.

Drug: Dextroamphetamine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Dextroamphetamine Sulfate
NDC 00555-0953
10 mg/1 Tablet
Oral
Teva Pharmaceuticals USA, Inc. Rx · CII
Recalling firm
Teva Pharmaceuticals USA
NDC code
0555-0953-02
Origin
PA, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1408-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Dextroamphetamine recalls

See all
Class II · Moderate risk

Dextroamphetamine Saccharate

Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.

Ongoing Labeling / mix-up Lannett Company Inc. D-0660-2026

Other recalls by Teva Pharmaceuticals USA

All 2014 recalls